Commercial manufacturing

Fermion has two commercial USFDA and EMA approved API manufacturing sites.

• Total volume of reactors 325 m³
• Reactor sizes vary from 60 l to 6300 l
• Annual API capacity of over 400 metric tons
• Cytotoxic APIs, steroids and conventional molecules

Fermion’s Hanko site handles production of higher volume products, whereas Fermion’s Oulu site focuses more on smaller volume high potency APIs. Both Oulu and Hanko sites have been designed to meet increasingly strict requirements of both regulatory authorities and customers. The first units of both plants having been built already during the 1970’s, Fermion has continuously upgraded the sites unit by unit to meet the highest industry standards. These development steps have been taken in order to better serve our customers as well as the actual patients. During the last decade the areas of special focus have been

• investments for high containment and safe processes to protect both employees and products including closed charging, CIP (cleaning-in-place), closed discharging, airlocks and gloveboxes
• environmental investments to minimise any environmental footprint related to VOC incineration or cryogenic condensation, hazardous waste, API containing waste streams and energy efficacy including CO2 reduction
• investments for high level automation systems to improve efficiency, process robustness and safety

We have capabilities to commercially manufacture highly potent OEB5 APIs from a scale of 1 - 2kg per batch up to one metric ton. This includes all aspects from chemistry to final handling including micronization and packaging. The table below describes the batch sizes and containment levels in our laboratory and production facilities